BioSensics Announces a $4.3M Grant Award from NIH to Develop Tools for Continuous, Remote Monitoring of Cognitive Decline

Dr. Joseph Gwin, Vice President of Research and Development at BioSensics, announced a $4.3M grant award from the National Institutes of Health (NIH) during his presentation at DPharm: Disruptive Innovations to Advance Clinical Trials last Tuesday. With this grant award, BioSensics will develop technology for continuous, remote monitoring of cognitive decline. This technology will enable objective assessment of instrumental activities of daily living, life space, and digital social interactions, which are biomarkers of many diseases and disorders from Alzheimer’s disease and dementia to depression. With the addition of this new technology, BioSensics will expand the capabilities of its Sensor-Integrated Digital Platform for Clinical Trials to include tools for objective measurement of cognitive and mental health.

The 3-year project will be conducted in collaboration with Baylor College of Medicine. The solution, which consists of a wearable movement sensor, GPS, and software for measuring digital social interactions, will have impacts in both clinical trials and clinical practice.

“BioSensics offers a wide range of solutions and services to measure movement and mobility related endpoints in clinical trials. We are thrilled to have the support of the NIH to further expand our offerings to measure endpoints that are directly relevant to a wide range of mental and cognitive disorders,” said Dr. Gwin.

For additional information, please contact clinicaltrials@biosensics.com.

See the full press release here.